Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Medical Genetics · Mucopolysaccharidosis type I

What Specialists Are Needed for MPS I Long-Term Care?

At a Glance

Children with MPS I require a multidisciplinary care team led by a metabolic geneticist. Long-term care involves routine surveillance including annual or semi-annual echocardiograms, sleep studies, eye and hearing exams, and specialized cervical spine imaging to prevent severe complications.

Mucopolysaccharidosis type I (MPS I) is a complex, multisystemic condition, which means it affects many different parts of the body as your child grows [1][2]. Because the condition changes over time, long-term care requires a comprehensive, team-based approach to monitor health, manage symptoms, and prevent complications before they become severe [3][4].

The cornerstone of your child’s care will be a multidisciplinary care team led by a metabolic geneticist [1][5]. This specialist acts as the “captain” of your child’s medical team, expertly coordinating care among various specialists, managing treatments like enzyme replacement therapy (ERT) or monitoring after stem cell transplantation, and ensuring that all routine surveillance is up to date [6][7].

Key Specialists on Your Child’s Care Team

Depending on your child’s specific diagnosis (severe Hurler syndrome versus attenuated Hurler-Scheie or Scheie syndromes) and their individual symptoms, their care team will likely include:

  • Metabolic Geneticist: Oversees the big picture, coordinates treatments, and tracks the overall progression of the disease [5][8].
  • Cardiologist: Monitors the heart for valve dysfunction and enlargement, which are common early features of MPS I [9][10].
  • Pulmonologist / Sleep Medicine Specialist: Manages airway complications and monitors for sleep apnea (breathing pauses during sleep) [4].
  • Ophthalmologist: Checks for eye problems like corneal clouding and optic nerve issues [11][12].
  • Audiologist & ENT (Ear, Nose, and Throat Specialist): Manages recurrent ear infections and monitors for hearing loss, which is highly prevalent in children with MPS I [13].
  • Orthopedist & Neurosurgeon: Monitors the skeleton and spine, particularly looking for dangerous pressure on the spinal cord or brain [2][14].
  • Pediatric Anesthesiologist: Because children with MPS I often have complex airways and sensitive necks, any procedure requiring anesthesia or sedation must be handled by an anesthesiologist experienced with MPS I [4][2].
  • Developmental Pediatrician & Neuropsychologist: Tracks cognitive and developmental milestones. While severe cognitive decline is primarily seen in the Hurler subtype, all children with MPS I benefit from developmental monitoring to ensure they receive appropriate learning support [1][4].
  • Physical (PT) & Occupational Therapists (OT): Manages dysostosis multiplex (progressive bone and joint stiffness) to maximize mobility and daily function [4][3].
  • Pediatric Dentist: Dental anomalies and enlarged gums are common in MPS I, requiring specialized routine care that accounts for airway safety [4].

Practical Tip: Managing all these appointments is a full-time job. Ask your metabolic geneticist or hospital to connect you with a Complex Care Coordinator or a social worker to help juggle scheduling and insurance.

Routine Surveillance Tests and Guidelines

Consistent, routine monitoring is the standard of care for all children with MPS I [15][4]. This surveillance detects slow-moving changes in the body so that interventions can happen early [1][16]. Your metabolic geneticist will create a personalized schedule and regularly check routine labs (such as urinary GAG levels) to track disease activity, but standard surveillance generally requires the following tests on an annual or semi-annual (twice a year) basis:

1. Echocardiograms (Heart)

Echocardiograms (ultrasounds of the heart) are required annually or semi-annually to screen for cardiac complications [17][9]. MPS I can cause the heart valves to thicken and leak (valvulopathy), and can lead to progressive abnormalities in the heart muscle [10][18]. Catching these changes early allows cardiologists to adjust medications or plan for surgical interventions if needed [19].

2. Sleep Studies and Lung Tests (Airway/Apnea)

Children with MPS I are at high risk for narrowed airways and obstructive sleep apnea [3][4]. Regular sleep studies (polysomnography) are necessary to monitor how well your child breathes at night. If apnea is detected, your team may recommend interventions like continuous positive airway pressure (CPAP) machines or tonsil removal. As your child grows older and can cooperate, awake Pulmonary Function Tests (PFTs) are often added to track lung capacity [4].

3. Eye Exams

Comprehensive eye exams are needed annually or semi-annually to monitor for corneal opacification (clouding of the clear front part of the eye) and optic nerve sheath abnormalities [20][11]. Without regular monitoring and timely treatment, these issues can lead to significant vision loss [12].

4. Hearing Tests (Audiology)

Because hearing loss is extremely common in MPS I, comprehensive audiological evaluations are recommended annually [13][21]. Keeping track of your child’s hearing is vital for their speech development, learning, and daily communication. If hearing loss is detected, your team can help with hearing aids or ear tubes [13].

5. Cervical Spine Imaging (X-rays and MRIs)

One of the most critical parts of long-term care for MPS I involves monitoring the neck and spine [2][4]. Children with MPS I frequently develop odontoid dysplasia (an underdeveloped bone in the neck) and cervical canal stenosis (narrowing of the spinal canal), which can lead to spinal cord compression and instability [22][23]. Regular cervical spine X-rays and neuroimaging, such as brain and spine MRIs, are required to catch these problems before they cause permanent neurological damage [2][24]. Because MRIs often require sedation in young children, this imaging should always be coordinated by your metabolic geneticist and an experienced pediatric anesthesiologist [2].

Common questions in this guide

Who should lead my child's MPS I care team?
Your child's care should be led by a metabolic geneticist. This specialist acts as the team captain, coordinating care among other experts, managing treatments like enzyme replacement therapy, and ensuring routine surveillance is up to date.
What heart tests are required for MPS I surveillance?
Children with MPS I need an echocardiogram, or ultrasound of the heart, once or twice a year. This test checks for thickened or leaking heart valves and changes in the heart muscle so cardiologists can adjust care early.
Why does my child need regular sleep studies for MPS I?
Children with MPS I are at high risk for narrowed airways and obstructive sleep apnea. Regular sleep studies monitor nighttime breathing so your team can intervene early with treatments like CPAP machines or tonsil removal if needed.
Why is specialized anesthesia so important for a child with MPS I?
Because children with MPS I often have complex airways and sensitive necks, any procedure requiring sedation or anesthesia can be risky. An experienced pediatric anesthesiologist is critical for keeping your child's airway safe during surgeries or MRIs.
How often should a child with MPS I get cervical spine MRIs?
The exact frequency depends on your child's specific MPS I subtype and symptoms, but regular monitoring is crucial. Your metabolic geneticist will create a personalized schedule to check for dangerous narrowing or instability in the neck and spine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How frequently should my child's specific MPS I subtype require updated cervical spine MRIs, and who will coordinate the specialized anesthesia for it?
  2. 2.Can you refer us to a complex care coordinator or social worker who can help me schedule and manage these multiple specialist appointments?
  3. 3.What specific cognitive and developmental milestones should we be tracking for my child's subtype, and who will monitor them?
  4. 4.Who should I contact in an emergency to ensure any surgical or airway interventions are handled by an anesthesiologist experienced with MPS I?
  5. 5.When should we begin introducing awake Pulmonary Function Tests (PFTs) alongside our regular sleep studies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Clinical outcomes of exclusive enzyme therapy (laronidase) in a cohort of patients with mucopolysaccharidosis type I.

    Guffon N, Pettazzoni M, Pangaud N, et al.

    Orphanet journal of rare diseases 2025; doi:10.1186/s13023-025-04157-6.

    PMID: 41353341
  2. 2

    Neuroimaging and spinal manifestations of mucopolysaccharidosis type I: Insights from a pediatric case.

    Boujida N, Jabour S, Elaitari K, et al.

    Radiology case reports 2025; (20(12)):5795-5799 doi:10.1016/j.radcr.2025.08.011.

    PMID: 40989062
  3. 3

    Challenges in Diagnosing and Managing Hurler Syndrome: A Case Report.

    Achiatar LS, Hazoor HB, Adwani R, et al.

    Cureus 2024; (16(8)):e67056 doi:10.7759/cureus.67056.

    PMID: 39286678
  4. 4

    New recommendations for the care of patients with mucopolysaccharidosis type I.

    Bay L, Amartino H, Antacle A, et al.

    Archivos argentinos de pediatria 2021; (119(2)):e121-e128 doi:10.5546/aap.2021.eng.e121.

    PMID: 33749201
  5. 5

    Acute Illness Protocol for Maple Syrup Urine Disease.

    Rodan LH, Aldubayan SH, Berry GT, Levy HL

    Pediatric emergency care 2018; (34(1)):64-67 doi:10.1097/PEC.0000000000001299.

    PMID: 29095391
  6. 6

    Is it Pompe Disease? Australian diagnostic considerations.

    Tchan M, Henderson R, Kornberg A, et al.

    Neuromuscular disorders : NMD 2020; (30(5)):389-399 doi:10.1016/j.nmd.2020.03.007.

    PMID: 32418839
  7. 7

    Emergency Management of Inherited Metabolic Disorders in Acute Surgical and Trauma Settings.

    Furuta Y, Tinker RJ, Grochowsky AR, Phillips JA

    The American surgeon 2026; (92(5)):1463-1472 doi:10.1177/00031348251403079.

    PMID: 41275486
  8. 8

    Acute Illness Protocol for Organic Acidemias: Methylmalonic Acidemia and Propionic Acidemia.

    Aldubayan SH, Rodan LH, Berry GT, Levy HL

    Pediatric emergency care 2017; (33(2)):142-146 doi:10.1097/PEC.0000000000001028.

    PMID: 28141776
  9. 9

    Natural history of cardiac findings in mucopolysaccharidosis type I: report from an international registry.

    Braunlin E, Bay L, Guffon N, et al.

    Cardiology in the young 2024; (34(2)):401-411 doi:10.1017/S1047951123003347.

    PMID: 37850463
  10. 10

    Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.

    Baldo G, Tavares AM, Gonzalez E, et al.

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2017; (27()):45-50 doi:10.1016/j.carpath.2017.01.001.

    PMID: 28104572
  11. 11

    Dilated Optic Nerve Sheath in Mucopolysaccharidosis I: Common and Not Necessarily High Intracranial Pressure.

    Huang S, Lund T, Orchard P, et al.

    AJNR. American journal of neuroradiology 2023; (44(1)):91-94 doi:10.3174/ajnr.A7755.

    PMID: 36581456
  12. 12

    Mucopolysaccharidosis Type I and Bilateral Optic Disc Edema.

    Gratton SM, Neerukonda T

    Neuro-ophthalmology (Aeolus Press) 2019; (43(6)):394-396 doi:10.1080/01658107.2018.1520903.

    PMID: 32165899
  13. 13

    Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

    Wolfberg J, Chintalapati K, Tomatsu S, Nagao K

    Diagnostics (Basel, Switzerland) 2020; (10(8)) doi:10.3390/diagnostics10080554.

    PMID: 32759694
  14. 14

    Markedly Elevated Intracranial Pressure Treated With Cranial Vault Expansion, Instead of CSF Shunting, in a Child With Hurler-Scheie Syndrome and Multiple Suture Craniosynostosis.

    Ching JA, Troy JS, Ruas EJ, et al.

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 2019; (56(3)):395-399 doi:10.1177/1055665618777906.

    PMID: 29791186
  15. 15

    Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I.

    Jameson E, Jones S, Remmington T

    The Cochrane database of systematic reviews 2019; (6()):CD009354 doi:10.1002/14651858.CD009354.pub5.

    PMID: 31211405
  16. 16

    Progressive Hand Stiffness and Numbness in a Child: An Atypical Neurological Presentation of Scheie Syndrome-A Case Report.

    Alharthi AS, Hassan CI, Alsharkawy AA, et al.

    Neurology international 2025; (17(12)) doi:10.3390/neurolint17120205.

    PMID: 41441225
  17. 17

    Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I.

    Sugiura K, Kubo T, Ochi Y, et al.

    Molecular genetics and metabolism reports 2020; (25()):100662 doi:10.1016/j.ymgmr.2020.100662.

    PMID: 33101981
  18. 18

    Clinical and Molecular Characterization of Patients with Mucopolysaccharidosis Type I in an Algerian Series.

    Tebani A, Zanoutene-Cheriet L, Adjtoutah Z, et al.

    International journal of molecular sciences 2016; (17(5)).

    PMID: 27196898
  19. 19

    Urgent resection of a giant left atrial appendage aneurysm and mitral valve replacement in a complex case of Hurler-Scheie syndrome.

    Brazier A, Hasan R, Jenkins P, Hoschtitzky A

    BMJ case reports 2015; (2015()).

    PMID: 26546621
  20. 20

    Successful treatment of corneal hypertrophic scar in Hurler syndrome.

    Koosha N, Irajpour M, Rostamiyan Z, et al.

    Clinical case reports 2024; (12(7)):e9112 doi:10.1002/ccr3.9112.

    PMID: 38919886
  21. 21

    Mucopolysaccharidosis Type I.

    Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al.

    Diagnostics (Basel, Switzerland) 2020; (10(3)) doi:10.3390/diagnostics10030161.

    PMID: 32188113
  22. 22

    Chiari I malformation and syringomyelia in mucopolysaccharidosis type I (Hurler syndrome) treated with posterior fossa decompression: Case report and review of the literature.

    Makler V, Goldstein CL, Hoernschemeyer D, Tanaka T

    Surgical neurology international 2017; (8()):80 doi:10.4103/sni.sni_463_16.

    PMID: 28607814
  23. 23

    Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.

    Hsu YH, Liu RS, Lin WL, et al.

    Orphanet journal of rare diseases 2017; (12(1)):109 doi:10.1186/s13023-017-0649-6.

    PMID: 28595620
  24. 24

    Mucopolysaccharidoses Causing Valvular Heart Disease: Report and Review of Surgical Management.

    Encarnacion CO, Hang D, Earing M, Mitchell ME

    World journal for pediatric & congenital heart surgery 2020; (11(4)):NP22-NP24 doi:10.1177/2150135117690105.

    PMID: 28421916

This page provides educational information about building a care team for children with MPS I. Always consult your child's metabolic geneticist or complex care coordinator for personalized medical advice and exact surveillance schedules.

Get notified when new evidence is published on Mucopolysaccharidosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.